Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells.

Goltsov AA, Fang B, Pandita TK, Maru DM, Swisher SG, Hofstetter WL.

Ann Thorac Surg. 2018 Feb;105(2):363-370. doi: 10.1016/j.athoracsur.2017.09.003. Epub 2017 Dec 7.

PMID:
29223420
2.

Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.

Li L, Yang G, Ren C, Tanimoto R, Hirayama T, Wang J, Hawke D, Kim SM, Lee JS, Goltsov AA, Park S, Ittmann MM, Troncoso P, Thompson TC.

Mol Oncol. 2013 Jun;7(3):484-96. doi: 10.1016/j.molonc.2012.12.005. Epub 2012 Dec 31.

3.

Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.

Tahir SA, Kurosaka S, Tanimoto R, Goltsov AA, Park S, Thompson TC.

Cancer Biol Ther. 2013 Feb;14(2):117-26. doi: 10.4161/cbt.22633. Epub 2012 Oct 31.

4.

Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer.

Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, Thompson TC.

Mol Cancer Res. 2012 Feb;10(2):218-29. doi: 10.1158/1541-7786.MCR-11-0451. Epub 2011 Dec 5.

5.

GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.

Li L, Ren C, Yang G, Fattah EA, Goltsov AA, Kim SM, Lee JS, Park S, Demayo FJ, Ittmann MM, Troncoso P, Thompson TC.

Cancer Res. 2011 Dec 15;71(24):7694-704. doi: 10.1158/0008-5472.CAN-11-1714. Epub 2011 Oct 24.

6.

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy.

Sonpavde G, Thompson TC, Jain RK, Ayala GE, Kurosaka S, Edamura K, Tabata K, Ren C, Goltsov AA, Mims MP, Hayes TG, Ittmann MM, Wheeler TM, Gee A, Miles BJ, Kadmon D.

Clin Cancer Res. 2011 Nov 15;17(22):7174-82. doi: 10.1158/1078-0432.CCR-11-1899. Epub 2011 Sep 20.

7.

Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.

Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC.

Mol Cancer Res. 2009 Nov;7(11):1781-91. doi: 10.1158/1541-7786.MCR-09-0255. Epub 2009 Nov 10.

8.

Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression.

Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, Fattah EA, Rajagopalan K, Timme TL, Park S, Kurosaka S, Edamura K, Tanimoto R, Demayo FJ, Goltsov AA, Thompson TC.

Mol Cancer Res. 2009 Sep;7(9):1446-55. doi: 10.1158/1541-7786.MCR-09-0071. Epub 2009 Sep 8.

9.

Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer.

Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC.

Cancer Res. 2008 Feb 1;68(3):731-9. doi: 10.1158/0008-5472.CAN-07-2668.

10.

Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-c-Jun-NH2 kinase signaling.

Li L, Abdel Fattah E, Cao G, Ren C, Yang G, Goltsov AA, Chinault AC, Cai WW, Timme TL, Thompson TC.

Cancer Res. 2008 Jan 15;68(2):434-43. doi: 10.1158/0008-5472.CAN-07-2931.

11.

Identification and characterization of RTVP1/GLIPR1-like genes, a novel p53 target gene cluster.

Ren C, Ren CH, Li L, Goltsov AA, Thompson TC.

Genomics. 2006 Aug;88(2):163-72. Epub 2006 May 22.

12.

mRTVP-1, a novel p53 target gene with proapoptotic activities.

Ren C, Li L, Goltsov AA, Timme TL, Tahir SA, Wang J, Garza L, Chinault AC, Thompson TC.

Mol Cell Biol. 2002 May;22(10):3345-57.

13.

RFLP discordance in a PKU family due to a deletion in the PAH gene.

Bosco P, Ceratto N, Cali F, Goltsov AA, Eisensmith RC, Novelli G, Dalla Piccola B, Romano V.

Turk J Pediatr. 1996 Oct-Dec;38(4):497-504.

PMID:
8993180
14.

Phenylketonuria in Costa Rica: preliminary spectrum of PAH mutations and their associations with highly polymorphic haplotypes.

Santos M, Kuzmin AI, Eisensmith RC, Goltsov AA, Woo SL, Barrantes R, de C├ęspedes C.

Hum Hered. 1996 May-Jun;46(3):128-31.

PMID:
8860005
15.

Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population.

Eisensmith RC, Martinez DR, Kuzmin AI, Goltsov AA, Brown A, Singh R, Elsas LJ II, Woo SL.

Pediatrics. 1996 Apr;97(4):512-6.

PMID:
8632937
16.

Complete spectrum of PAH mutations in Tataria: presence of Slavic, Turkic and Scandinavian mutations.

Kuzmin AI, Eisensmith RC, Goltsov AA, Sergeeva NA, Schwartz EI, Woo SL.

Eur J Hum Genet. 1995;3(4):246-55.

PMID:
8528673
17.

Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans.

Eisensmith RC, Goltsov AA, O'Neill C, Tyfield LA, Schwartz EI, Kuzmin AI, Baranovskaya SS, Tsukerman GL, Treacy E, Scriver CR, et al.

Am J Hum Genet. 1995 Jan;56(1):278-86.

18.
19.

A single polymorphic STR system in the human phenylalanine hydroxylase gene permits rapid prenatal diagnosis and carrier screening for phenylketonuria.

Goltsov AA, Eisensmith RC, Naughton ER, Jin L, Chakraborty R, Woo SL.

Hum Mol Genet. 1993 May;2(5):577-81.

PMID:
8100164
20.

Associations between mutations and a VNTR in the human phenylalanine hydroxylase gene.

Goltsov AA, Eisensmith RC, Konecki DS, Lichter-Konecki U, Woo SL.

Am J Hum Genet. 1992 Sep;51(3):627-36.

21.

Detection of the XmnI RFLP at the human PAH locus by PCR.

Goltsov AA, Eisensmith RC, Woo SL.

Nucleic Acids Res. 1992 Feb 25;20(4):927. No abstract available.

Supplemental Content

Loading ...
Support Center